Radiotherapy & Oncology
Volume 96, Issue 2 , Pages 204-208, August 2010

Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy

  • Neil K. Taunk

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
  • ,
  • Sharad Goyal

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
    • Corresponding Author InformationCorresponding author at: Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08903, USA.
  • ,
  • Meena S. Moran

      Affiliations

    • Department of Therapeutic Radiology, Yale University School of Medicine, USA
  • ,
  • Qifeng Yang

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
    • Department of Breast Surgery, Qilu Hospital/Shandong University, People’s Republic of China
  • ,
  • Rahul Parikh

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
  • ,
  • Bruce G. Haffty

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA

Received 8 September 2009; received in revised form 23 February 2010; accepted 7 March 2010. published online 25 March 2010.

Abstract 

Background

Insulin-like growth factor (IGF) receptor is a key receptor in apoptotic protection, cell adhesion, longevity, and transformation into a cancerous cell and can induce malignant changes in the presence of the IGF ligand. Over-expression of IGF-1R has been associated with resistance to radiation. Inhibitors of IGF-1R have been shown to enhance tumor radiation sensitivity and amplify radiation therapy-induced apoptosis. The purpose of this study is to evaluate the prognostic significance of IGF-1R expression in patients with breast cancer treated with breast conserving therapy.

Materials and methods

Paraffin specimens from 345 women with early stage breast cancer treated with BCT were constructed into tissue microarrays and stained for IGF-1R, COX-2 and p53. The molecular profiles were correlated with clinical-pathologic factors, overall, local, and distant relapse-free survival. The association between IGF-1R, other co-variables, and outcome was assessed.

Results

IGF-1R over-expression was identified in 197 cases (57%). IGF-1R over-expression was found to be correlated with African-American race (p=0.0233), p53 status (p=0.0082) and COX-2 expression (p<0.0001). While IGF-1R over-expression was associated with lower overall survival (p=0.0224) in node-negative patients, there was no impact of IGF-1R expression on local control.

Conclusions

In node-negative patients, patients with high levels of IGF-1R were found to have a significant reduction in overall survival, but no apparent effect on local control. Given the limited published data on IGF-1R in early stage, conservatively treated patients, further studies investigating IGF-1R expression in this cohort are necessary.

Keywords: Early stage breast cancer, Insulin-like growth factor 1 receptor (IGF-1R), Radiation therapy, Molecular markers

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This abstract was presented as an oral presentation at the 2008 Translational Advances in Radiation Oncology and Cancer Imaging Symposium in Arlington, Virginia on October 17–18, 2008 by N.K.T., who also received an ASTRO travel grant for this work. The Breast Cancer Research Foundation provided support to B.G.H. for this research.

PII: S0167-8140(10)00161-1

doi:10.1016/j.radonc.2010.03.009

Radiotherapy & Oncology
Volume 96, Issue 2 , Pages 204-208, August 2010